Sernova Corp
TSX VENTURE : SVA

Sernova Corp

February 25, 2011 06:20 ET

Sernova to Present at BioPartnering North America Conference

LONDON, ONTARIO--(Marketwire - Feb. 25, 2011) - Sernova Corp. (TSX VENTURE:SVA) today announced that the Company will present to a select group of biotech industry investors and potential alliance partners at the BioPartnering North America Conference in Vancouver, British Columbia at 10:45 a.m. on March 1, 2011.

Sernova's President & Chief Executive Officer, Dr. Philip Toleikis, will provide an update on the Sernova's recent progress including recent pre-clinical studies, manufacturing and plans for advancement of the Company's Cell Pouch System™ into human clinical trials. 

The Cell Pouch System™ is a proprietary medical device which may offer a revolutionary improvement over the current practice of injecting therapeutic cells into blood vessels. Based on previous pre-clinical research, the Cell Pouch System™ becomes a vascularised organ-like endocrine structure when placed in the body, providing the microcirculation thought to be essential to early function and long-term survival of therapeutic cells. Sernova has conducted efficacy studies in small and large animal models of diabetes and shown the device with insulin-producing islets to control blood glucose levels long-term without the need for daily insulin injections. Sernova believes the Cell Pouch System™ has the potential for a wide range of uses in cell therapy including the treatment of diabetes, haemophilia, spinal cord injury, Parkinson's disease and other chronic debilitating diseases and is currently seeking corporate partnerships as part of a strategy to demonstrate the broad utility of the Cell Pouch System™. 

About Sernova

Sernova Corp. is a Canadian-based health sciences company focused on product development and commercialization of innovative proprietary platform medical technologies in the cell therapy arena such as the Cell Pouch System™ to provide a safe and efficacious environment for therapeutic cells and Sertolin™, a technology which, when combined with cell therapy, may protect therapeutic cells without the need for patients to take anti-rejection drugs.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors - including availability of funds, the results of financing efforts, the results of research and product development activities -- that could cause actual results to differ materially from Sernova's expectations are disclosed in Sernova's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information